Exact Sciences Q3 Earnings: Profitability Goal Execution Momentum Building Into 2023

Nov. 09, 2022 10:45 PM ETExact Sciences Corporation (EXAS)4 Comments
Bashar Issa profile picture
Bashar Issa


  • Exact Sciences demonstrated exceptional financial discipline during the third quarter, delivering robust growth with lower operating expenditure.
  • New product launches and label expansion of existing products support the company's growth projections.
  • Competition is increasing, but the company's unique market position, namely in its core CRC screening market, offers some competitive moat.
New Year 2023 Goals on Blackboard Background

phototechno/iStock via Getty Images

Investment Thesis

Exact Sciences (NASDAQ:EXAS) is trading at $39 per share, up 20% since the company reported its third-quarter results last week after the Wisconsin-based gene testing lab beat EPS estimates by a wide margin, demonstrating operational flexibility that signals an ability to

This article was written by

Bashar Issa profile picture
Bashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London and a Bachelor's degree in Economics from Middlesex University.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.